The development of antidepressants that inhibit the P2X7 receptor is currently in the clinical phase (Bhattacharya and Jones, 2018; Drevets et al., 2022) for the treatment of therapy-resistant depression. The gene discussed is P2RX7; the disease is depressive disorder.